

Register Now!

2nd Annual Mount Sinai MASLD/MASH (NAFLD/NASH) Center of Excellence Symposium

October 11, 2024, 8:00am – 4:15pm Virtual Symposium

Course Directors

Meena B. Bansal, MD Professor of Medicine System Chief, Division of Liver Diseases Director, Mount Sinai MASLD/MASH (NAFLD/NASH) Center of Excellence

Scott L. Friedman, MD Dean for Collaborative Research and Partnerships Fishberg Professor of Medicine

Andrea D. Branch, PhD Professor of Medicine and Director of Basic and Translational Research Institute for Liver Medicine

Guest Faculty Manal F. Abdelmalek, MD Naim Alkhouri, MD, MPH, FAASLD Mazen Noureddin, MD, MHSc Mary Rinella, MD

Online Registration: https://mssm.cloud-cme.com/MASH



PROGRAM (Subject to Change)

2nd Annual Mount Sinai MASLD/MASH (NAFLD/NASH) Center of Excellence Symposium, October 11, 2024

This symposium will provide a comprehensive overview of the diagnosis, risk stratification, management including co-morbidities, and emerging therapies for MASLD/MASH (NAFLD/NASH).

8:00 - 8:15am	Introduction-the BIG Picture Metabolic Dysfunction Associated Steatohepatitis (MASH)	Scott L. Friedman, MD
8:15 - 8:35	Hot Topics EASL Review of Emerging MASH Data Manal F. Abdelmalek, MD, MPH, FAASLD	
8:35 - 8:55	Cracking the Code Making the Diagnosis, Risk Stratification, and Prognosis Prediction in MASLD/MAS	6H Meena B. Bansal, MD
8:55 - 9:15	The Clues Within Overview of Serum Markers of Liver Fibrosis and Metabolic Health	Mazen Noureddin, MD, MHSc
9:15 - 9:35	It's Complicated Impact of Environmental and Genomic Factors on Fibrosis Progression in Adults with MASH Andrea D. Branch, PhD	
9:35 - 10:00	Seeing is Believing Overview of Imaging Modalities for the Assessment of MASLD/MASH	Bachir Taouli, MD
10:00 - 10:15	Break	
10:15 - 10:35	Powering the Future Leveraging New AI algorithms for Risk Stratification and Prediction of Outcomes	Jörn M. Schattenberg, MD
10:35 - 10:55	Eye of the Storm Intersection of Genetics, Lifestyle, and Environment in Pediatric MASLD/MASH	Jaime Chu, MD
10:55 - 11:10	Catch Me When You Can Maximizing Opportunities for Engagement by Screening for MASLD/MASH in OB/G	YN Tatyana Kushner, MD
11:10 - 11:30	Screening for MASLD/MASH from PCP Perspective	Fernando Carnavali, MD
11:30 - 12:15	How to Speak with Patients Workshop Patient Advocacy Groups/Patient Panel Real Time Needs Assessment	Michael Betel, Henry Chang
12:15 - 1:00pm	Lunch	
1:00 - 1:20	Empowering Change Lifestyle, Medical, and Surgical Management of Obesity and Diabetes, and their Role in the Management of Patients with MASLD/MASH	Reshmi I. Srinath, MD
1:20 - 1:40	Finding a Needle in a Haystack MASLD/MASH and HCC	Augusto Villanueva, MD PhD
1:40 - 2:00	We Have a Drug for That Targeting Thyroid Hormone-b Signaling and Other Emerging Therapies in the Treatment of MASH	Meena B. Bansal, MD
2:00 - 2:25	The Crystal Ball Predicting and Managing Cardiovascular Risk in Patients with MASLD/MASH	Anu Lala, MD
2:25 - 2:45	Timing is Everything GLP-1 (and Combo Drugs)-Mechanism of Action and Their Impact on MASH	Mary Rinella, MD
2:45 - 3:00	Break	
3:00 - 400	Ask the Experts Making Sense of It All (Case Based Discussion) and Open Q and A from Attendee	s Meena Bansal and others

FACULTY

2nd Annual Mount Sinai MASLD/MASH (NAFLD/NASH) Center of Excellence Symposium, October 11, 2024



Manal F. Abdelmalek, MD, MPH, FAASLD

Professor of Medicine Division of Gastroenterology and Hepatology Director, MASLD Clinical Research Mayo Clinic Rochester, MN

Meena B. Bansal, MD

Professor of Medicine System Chief, Division of Liver Diseases Director, Mount Sinai MASLD/MASH (NAFLD/NASH) Center of Excellence

Michael Betel

President and Founder Fatty Liver Alliance

Andrea D. Branch, PhD

Professor of Medicine Director of Basic and Translational Research Institute for Liver Medicine Icahn School of Medicine at Mount Sinai

Fernando Carnavali, MD

Associate Professor of Medicine Division Chief General Internal Medicine Department of Medicine Icahn School of Medicine at Mount Sinai Mount Sinai Morningside/ Mount Sinai West

Henry E. Chang

Executive Director Fatty Liver Foundation

Jaime Chu, MD

Associate Professor of Pediatrics, Division of Pediatric Hepatology Medical Director, Pediatric Liver Transplantation Icahn School of Medicine at Mount Sinai

Scott L. Friedman, MD

Dean for Collaborative Research and Partnerships Fishberg Professor of Medicine Icahn School of Medicine at Mount Sinai

Tatyana Kushner, MD, MSCE

Associate Professor of Medicine, Liver Diseases Associate Professor of Obstetrics, Gynecology and Reproductive Science Icahn School of Medicine at Mount Sinai

Anu Lala, MD

Associate Professor, Department of Medicine, Cardiology, and Population Health Science and Policy Icahn School of Medicine at Mount Sinai

Mazen Noureddin, MD, MHSc

Professor of Medicine Houston Methodist Hospital Director Houston Research Institute Houston, TX

Mary Rinella, MD

Professor of Medicine Director, Metabolic and Steatotic Liver Program Director of Clinical Trials, Section of Gastroenterology and Hepatology University of Chicago School of Medicine Chicago, IL

Jörn M. Schattenberg, MD

Professor of Medicine Director of the Department of Internal Medicine II Gastreoenterology, Hepatology, Endocrinology and Nutritional Sciences Saarland University Medical Center Homburg, Germany

Reshmi I. Srinath, MD

Associate Professor Division of Endocrinology, Diabetes and Bone Disease Director, Mount Sinai Weight and Metabolism and Management Program Icahn School of Medicine at Mount Sinai

Bachir Taouli, MD, MHA

Professor of Radiology Department of Diagnostic, Molecular and Interventional Radiology BioMedical Engineering and Imaging Institute Icahn School of Medicine at Mount Sinai

Augusto Villanueva, MD PhD

Associate Professor of Medicine, Liver Diseases Associate Professor of Medicine, Hematology and Medical Oncology Icahn School of Medicine at Mount Sinai

CME INFORMATION

2nd Annual Mount Sinai MASLD/MASH (NAFLD/NASH) Center of Excellence Symposium, October 11, 2024

TARGET AUDIENCE

This program is intended for physicians and advanced practitioners practicing in the fields of general internal medicine, endocrinology, cardiology, gastroenterology, obesity medicine, and hepatology.

ACTIVITY DESCRIPTION

This symposium will provide a comprehensive overview of the diagnosis, risk stratification, management including co-morbidities, and emerging therapies for MASLD/MASH (NAFLD/NASH).

COURSE OBJECTIVES

Recognize MASLD/MASH (NAFLD/NASH) clinical course, risk stratification, outcomes, and management. Interpret and appropriately apply results of non-invasive tests for MASLD/MASH (NAFLD/NASH) to diverse patient populations.

ACCREDITATION

The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Icahn School of Medicine at Mount Sinai designates this live streamed activity for a maximum of 7.0 AMA PRA Category 1 Credit(s)[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

VERIFICATION OF ATTENDANCE

Will be provided to all professionals.

COURSE EVALUATION / CME CERTIFICATE

Complete the course evaluation and download your CME certificate. Visit our CME portal at https://mssm.cloud-cme.com.

SPECIAL NEEDS

The Icahn School of Medicine at Mount Sinai is in full compliance with provisions of the Americans with Disabilities Act (ADA) and is accessible for individuals with special needs. If you require special accommodations, email the Office of CME at cme@mssm.edu.

FACULTY DISCLOSURE

It is the policy of Icahn School of Medicine at Mount Sinai (ISMMS) to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-accredited educational activities. All faculty participating in the planning or implementation of an activity accredited by ISMMS are expected to disclose all of their financial relationships with ineligible companies existing within the prior 24 months. Relevant financial relationships will be mitigated and disclosed to learners before the activity takes place. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.

REGISTRATION FEES

- \$150 Industry
- \$75 Practicing Physicians
- \$50 Allied Health Professionals
- \$25 Residents/Fellows
- \$0 MSHS Residents/Fellows, Patients and Patient Advocates Email Francine.Pope@mssm.edu for a complimentary code





